Svenson M, Nedergaard S, Heegaard P M, Whisenand T D, Arend W P, Bendtzen K
Institute for Inflammation Research TA 7544, RHIMA Center, National University Hospital, Copenhagen, Denmark.
Eur J Immunol. 1995 Oct;25(10):2842-50. doi: 10.1002/eji.1830251020.
A recently described factor, interleukin-1 receptor antagonist binding factor (IL-1raBF), in serum of normal individuals is immunologically related to the interleukin-1 receptor type I (IL-1RI). It is presumably a soluble form of the receptor that binds exclusively to interleukin-1 receptor antagonist (IL-1ra). Recombinant soluble human IL-1RI expressed in COS cells (sIL-1RI) consists of the extracellular part of the receptor and binds all three known IL-1 species but preferentially to Il-1ra. We further characterized the sizes and binding of IL-1raBF and sIL-1RI to IL-1ra by polyacrylamide gel electrophoresis in the presence of sodium dodecylsulfate, ligand binding interference analyses, N-glycosidase treatment, concanavalin A affinity chromatography, and with the use of monoclonal antibodies (mAb) to human recombinant IL-1ra. We also evaluated the binding of IL-1ra to cellular IL-1RI on MRC5 fibroblasts and the interference afforded by the soluble receptors. The results show that the protein backbones of IL-1raBF and sIL-1RI are of similar size (approximately 35-40 kDa) and that there are differences in the glycosylation of the two molecules. These carbohydrates were necessary for optimal binding of both molecules to IL-1ra. Both factors blocked binding of IL-1ra to cellular IL-1RI, as did mAb to IL-1ra, but the sites on IL-1ra which bound to the mAb, and to IL-1raBF and sIL-1RI, differed. We conclude that there are important differences between the natural and recombinant forms of soluble IL-1RI and that IL-1ra binds differently to these molecules and to cellular IL-1RI.
最近在正常个体血清中发现的一种因子,即白细胞介素-1受体拮抗剂结合因子(IL-1raBF),在免疫学上与I型白细胞介素-1受体(IL-1RI)相关。它可能是一种仅与白细胞介素-1受体拮抗剂(IL-1ra)结合的可溶性受体形式。在COS细胞中表达的重组可溶性人IL-1RI(sIL-1RI)由受体的细胞外部分组成,能结合所有三种已知的白细胞介素-1,但优先结合IL-1ra。我们通过十二烷基硫酸钠存在下的聚丙烯酰胺凝胶电泳、配体结合干扰分析、N-糖苷酶处理、伴刀豆球蛋白A亲和层析以及使用针对人重组IL-1ra的单克隆抗体(mAb),进一步对IL-1raBF和sIL-1RI的大小以及它们与IL-1ra的结合进行了表征。我们还评估了IL-1ra与MRC5成纤维细胞上的细胞IL-1RI的结合以及可溶性受体所提供的干扰。结果表明,IL-1raBF和sIL-1RI的蛋白质骨架大小相似(约35 - 40 kDa),并且这两种分子的糖基化存在差异。这些碳水化合物对于两种分子与IL-1ra的最佳结合是必需的。这两种因子都能阻断IL-1ra与细胞IL-1RI的结合,抗IL-1ra的mAb也能阻断,但IL-1ra上与mAb、IL-1raBF和sIL-1RI结合的位点不同。我们得出结论,可溶性IL-1RI的天然形式和重组形式之间存在重要差异,并且IL-1ra与这些分子以及细胞IL-1RI的结合方式不同。